Published in Leukemia on January 01, 2013
Combined use of free light chain and heavy/light chain ratios allow diagnosis and monitoring of patients with monoclonal gammopathies: Experience of a single institute, with three exemplar case reports. Oncol Lett (2016) 0.75
Heavy/light chain ratio normalization prior to transplant is of independent prognostic significance in multiple myeloma: a BMT CTN 0102 correlative study. Br J Haematol (2016) 0.75
Suppression of uninvolved immunoglobulins defined by heavy/light chain pair suppression is a risk factor for progression of MGUS. Leukemia (2012) 1.44
Prognostic utility of intact immunoglobulin Ig'κ/Ig'λ ratios in multiple myeloma patients. Leukemia (2012) 1.23
Immunoglobulin gamma heavy chain gene with somatic hypermutation is frequently expressed in acute myeloid leukemia. Leukemia (2012) 1.15
International uniform response criteria for multiple myeloma. Leukemia (2006) 17.78
Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia (2008) 8.85
Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. Leukemia (2011) 4.47
Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma. Leukemia (2007) 3.95
International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia (2008) 3.41
Plasma cell labeling index and beta 2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma. Blood (1993) 2.98
Clinically relevant end points and new drug approvals for myeloma. Leukemia (2007) 2.91
Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia (2007) 2.76
Genetic aberrations and survival in plasma cell leukemia. Leukemia (2008) 2.69
International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple Myeloma. Leukemia (2009) 2.28
Chromosome abnormalities clustering and its implications for pathogenesis and prognosis in myeloma. Leukemia (2003) 2.28
Improvement of cast nephropathy with plasma exchange depends on the diagnosis and on reduction of serum free light chains. Kidney Int (2008) 2.21
Measurement of the intensity of cell surface antigen expression in B-cell chronic lymphocytic leukemia. Am J Clin Pathol (1994) 2.13
Prognostic value of the serum free light chain ratio in newly diagnosed myeloma: proposed incorporation into the international staging system. Leukemia (2008) 1.77
Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM). Leukemia (2010) 1.77
Plasma interleukin-6 and C-reactive protein levels in reactive versus clonal thrombocytosis. Am J Med (1994) 1.73
Prognostic value of chromosome 1q21 gain by fluorescent in situ hybridization and increase CKS1B expression in myeloma. Leukemia (2006) 1.71
Management of treatment-emergent peripheral neuropathy in multiple myeloma. Leukemia (2011) 1.70
A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy. Leukemia (2007) 1.66
Clinical significance of TP53 mutation in myeloma. Leukemia (2007) 1.62
Thalidomide in the treatment of plasma cell malignancies. J Clin Oncol (2001) 1.59
Clinical and biological significance of RAS mutations in multiple myeloma. Leukemia (2008) 1.56
The clinical aspects of biclonal gammopathies. Review of 57 cases. Am J Med (1981) 1.54
A phase I study of 153Sm-EDTMP with fixed high-dose melphalan as a peripheral blood stem cell conditioning regimen in patients with multiple myeloma. Leukemia (2005) 1.51
Early gastric cancer. Br J Surg (1992) 1.49
Complete resolution of reflex sympathetic dystrophy with thalidomide treatment. Arch Intern Med (2001) 1.47
Eligibility for hematopoietic stem-cell transplantation for primary systemic amyloidosis is a favorable prognostic factor for survival. J Clin Oncol (2001) 1.45
Suppression of uninvolved immunoglobulins defined by heavy/light chain pair suppression is a risk factor for progression of MGUS. Leukemia (2012) 1.44
Combining fluorescent in situ hybridization data with ISS staging improves risk assessment in myeloma: an International Myeloma Working Group collaborative project. Leukemia (2012) 1.43
Factor V. Methods Enzymol (1981) 1.43
Serum free light chain ratio as a biomarker for high-risk smoldering multiple myeloma. Leukemia (2012) 1.41
Isolation of functional human coagulation factor V by using a hybridoma antibody. Proc Natl Acad Sci U S A (1981) 1.40
Incidence of extramedullary disease in patients with multiple myeloma in the era of novel therapy, and the activity of pomalidomide on extramedullary myeloma. Leukemia (2011) 1.38
Evaluation and clinical correlations of bone marrow angiogenesis in myelofibrosis with myeloid metaplasia. Blood (2000) 1.36
Monoclonal antibodies to porcine factor VIII coagulant and their use in the isolation of active coagulant protein. Blood (1982) 1.34
Specificity of Mycobacterium tuberculosis antigen 5 determined with mouse monoclonal antibodies. Infect Immun (1984) 1.34
Alpha1-antitrypsin deficiency allele carriers among lung cancer patients. Cancer Epidemiol Biomarkers Prev (1999) 1.32
Deep venous thrombosis and thalidomide therapy for multiple myeloma. N Engl J Med (2001) 1.32
Melphalan and prednisone versus melphalan, prednisone and thalidomide for elderly and/or transplant ineligible patients with multiple myeloma: a meta-analysis. Leukemia (2011) 1.31
Higher risk of mismatch repair-deficient colorectal cancer in alpha(1)-antitrypsin deficiency carriers and cigarette smokers. Mol Genet Metab (2000) 1.28
Treatment of newly diagnosed myeloma. Leukemia (2008) 1.27
High levels of peripheral blood circulating plasma cells as a specific risk factor for progression of smoldering multiple myeloma. Leukemia (2012) 1.27
ABT-737, an inhibitor of Bcl-2 family proteins, is a potent inducer of apoptosis in multiple myeloma cells. Leukemia (2007) 1.25
Monoclonal gammopathies of undetermined significance. Hematol Oncol Clin North Am (1999) 1.23
Symptomatic subependymoma: a clinicopathological and flow cytometric study. J Neurosurg (1991) 1.23
Detection of myeloma cells in the peripheral blood by flow cytometry. Cytometry (1996) 1.22
Value of beta 2-microglobulin level and plasma cell labeling indices as prognostic factors in patients with newly diagnosed myeloma. Blood (1988) 1.21
Subependymal giant cell astrocytoma: a clinical, pathological, and flow cytometric study. Neurosurgery (1991) 1.20
Expression of VEGF and its receptors by myeloma cells. Leukemia (2003) 1.18
Sorafenib, a dual Raf kinase/vascular endothelial growth factor receptor inhibitor has significant anti-myeloma activity and synergizes with common anti-myeloma drugs. Oncogene (2009) 1.18
Multiple myeloma: circulating lymphocytes that express plasma cell antigens. Blood (1984) 1.17
Bortezomib, dexamethasone, cyclophosphamide and lenalidomide combination for newly diagnosed multiple myeloma: phase 1 results from the multicenter EVOLUTION study. Leukemia (2010) 1.14
Coexistence of aneuploid subclones within a myeloma cell line that exhibits clonal immunoglobulin gene rearrangement: clinical implications. Cancer Res (1993) 1.11
Primary lymph node plasmacytomas (plasmacytic lymphomas). Am J Clin Pathol (2001) 1.11
Long-term follow-up of IgM monoclonal gammopathy of undetermined significance. Semin Oncol (2003) 1.10
Prognostic significance of p53 immunostaining in epithelial ovarian cancer. J Clin Oncol (1994) 1.10
Impact of early relapse after auto-SCT for multiple myeloma. Bone Marrow Transplant (2008) 1.10
The significance of atypia and histologic malignancy in pilocytic astrocytoma of the cerebellum: a clinicopathologic and flow cytometric study. J Child Neurol (1994) 1.09
DNA ploidy and cell kinetic measurements as predictors of recurrence and survival in stages B2 and C colorectal adenocarcinoma. Cancer (1991) 1.05
Supratentorial pilocytic astrocytomas. A clinicopathologic, prognostic, and flow cytometric study of 51 patients. Cancer (1993) 1.05
Translocations involving the immunoglobulin heavy-chain locus are possible early genetic events in patients with primary systemic amyloidosis. Blood (2001) 1.05
Phyllodes tumor: clinicopathologic review of 60 patients and flow cytometric analysis in 30 patients. Hum Pathol (1992) 1.03
Disparities in the prevalence, pathogenesis and progression of monoclonal gammopathy of undetermined significance and multiple myeloma between blacks and whites. Leukemia (2011) 1.03
Relationship between elevated immunoglobulin free light chain and the presence of IgH translocations in multiple myeloma. Leukemia (2010) 1.03
Evaluation of DNA nuclear pattern as a prognostic determinant in resected pancreatic ductal adenocarcinoma. Ann Surg (1992) 1.03
Anemia after orchiectomy. Am J Hematol (1998) 1.02
Prognostic value of bone marrow angiogenesis in patients with multiple myeloma undergoing high-dose therapy. Bone Marrow Transplant (2004) 1.02
Peripheral blood B cell labeling indices are a measure of disease activity in patients with monoclonal gammopathies. J Clin Oncol (1988) 1.01
CD45 expression by bone marrow plasma cells in multiple myeloma: clinical and biological correlations. Leukemia (2005) 1.01
Effect of thalidomide on stem cell collection and engraftment in patients with multiple myeloma. Bone Marrow Transplant (2003) 1.01
Pomalidomide: the new immunomodulatory agent for the treatment of multiple myeloma. Blood Cancer J (2013) 1.01
Waldenström's macroglobulinemia. Oncologist (2000) 1.01
Risk of acute leukemia and myelodysplastic syndromes in patients with monoclonal gammopathy of undetermined significance (MGUS): a population-based study of 17 315 patients. Leukemia (2013) 1.00
Immunofluorescence labeling indices in myeloma and related monoclonal gammopathies. Mayo Clin Proc (1987) 1.00
A phase III randomized trial of thalidomide plus zoledronic acid versus zoledronic acid alone in patients with asymptomatic multiple myeloma. Leukemia (2012) 0.99
A monoclonal antibody reactive with 5-bromo-2-deoxyuridine that does not require DNA denaturation. Cytometry (1985) 0.99
High-dose therapy and autologous stem cell transplantation for multiple myeloma poorly responsive to initial therapy. Bone Marrow Transplant (2004) 0.99
Acquired immunodeficiency syndrome associated with blood-product transfusions. Ann Intern Med (1983) 0.99
Monoclonal autoantibodies promote central nervous system repair in an animal model of multiple sclerosis. J Neurosci (1994) 0.98
MRK003, a γ-secretase inhibitor exhibits promising in vitro pre-clinical activity in multiple myeloma and non-Hodgkin's lymphoma. Leukemia (2011) 0.98
Treatment of plasma cell dyscrasias with lenalidomide. Leukemia (2008) 0.97
Long-term outcome with lenalidomide and dexamethasone therapy for newly diagnosed multiple myeloma. Leukemia (2013) 0.97
High sensitivity cardiac troponin T in patients with immunoglobulin light chain amyloidosis. Heart (2014) 0.97
Immunophenotypic analysis of peripheral blood and bone marrow in the staging of B-cell malignant lymphoma. Blood (1999) 0.96
CD40 expression in malignant plasma cells. Role in stimulation of autocrine IL-6 secretion by a human myeloma cell line. J Immunol (1994) 0.96
Response to salvage therapies and outcome in patients with multiple myeloma relapsing after pomalidomide therapy. Leukemia (2011) 0.95
Single agent dexamethasone for pre-stem cell transplant induction therapy for multiple myeloma. Bone Marrow Transplant (2004) 0.95
Effect of thalidomide therapy on bone marrow angiogenesis in multiple myeloma. Leukemia (2004) 0.93
Primary plasma cell leukaemia: immunological and ultrastructural studies in 6 cases. Scand J Haematol (1985) 0.92
Alpha-1-antitrypsin phenotypes among patients with intracranial aneurysms. J Neurosurg (1996) 0.92
Acute leukemia with megakaryocytic differentiation: a study of 12 cases identified immunocytochemically. Blood (1984) 0.92
Ticks, spirochetes, and new diagnostic tests for Lyme disease. Mayo Clin Proc (1985) 0.92
Monoclonal antibodies to native noncollagenous bone-specific proteins. Proc Natl Acad Sci U S A (1984) 0.92
Lymphocyte subsets in primary sclerosing cholangitis. Dig Dis Sci (1987) 0.91
Prognostic factors in gliomas. A multivariate analysis of clinical, pathologic, flow cytometric, cytogenetic, and molecular markers. Cancer (1994) 0.90